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Abstract
Background: The decision to conduct a randomized controlled trial (RCT) in a field raises ethical as well as
scientific issues. From the clinical equipoise literature, future trials are justifiable if there is ”honest, professional
disagreement in the community of expert practitioners as to the preferred treatment”. Empirical data are sparse
about how clinicians apply the principles of equipoise to the justification of future RCTs. For example, selective
decontamination of the digestive tract (SDD) is not widely used in critical care practice despite the strength of the
evidence base and therefore provides a unique opportunity to learn how clinicians think about the ethics of further
RCTs in critical care.
Methods: In an international interview study of views of healthcare professionals about SDD, we undertook a
secondary analysis of qualitative data collected using a Theoretical Domains Framework of clinical behaviour. We
adopted a general descriptive approach to explore how physicians determined whether another RCT of SDD is
ethical. Following a constant comparison approach, three investigators reviewed 54 purposively chosen transcripts
from three international regions. We interpreted the data using thematic analysis.
Results: We grouped participants’ responses into four inter-related themes: 1) cultural norms about evidence and
practice within healthcare; 2) personal views about what evidence is current or applicable; 3) the interpersonal and
relational nature of professional decision making locally; and 4) an a priori commitment to future trials. The analysis
also identified several unresolved tensions regarding when a future RCT should be pursued. These tensions focused
on a clash between potential benefits to current individual patients and potential future harms to patients more
broadly.
Conclusions: Our study suggests that ethical decision making about future RCTs in the field of SDD does not rely
strongly on appeals to evidence, even when the quality of the evidence is reasonably high. Rather, “extra-evidential”
reasons, including social, professional, and relational factors, seem to influence opinions regarding the ethics of
future trials. Further work is required to see if these conclusions are applicable to other clinical topics and settings.
Keywords: Ethics, Clinical equipoise, Harm-benefit analysis, Critical care, Evidence-based medicine, Qualitative
research, Randomized controlled trials
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Background
Randomized controlled trials (RCTs) help to provide re-
liable information on the safety and efficacy of health-
care interventions. To have scientific and clinical utility,
an RCT of a novel intervention may be considered to
have a “window of opportunity” with respect to the ac-
cumulating knowledge base. If little evidence exists at
the proof-of-principle level, a large definitive RCT may
be premature, and it may be unjustifiable to expose pa-
tients to a potentially ineffective (or even harmful) treat-
ment in a subsequent trial. On the other hand, if the
safety, efficacy, and effectiveness of an intervention have
been rigorously established, a further RCT seems unlikely
to contribute meaningfully to knowledge. Unnecessary
repetition of RCTs is a more common problem than one
might think. Fergusson and colleagues describe a series of
64 RCTs of aprotinin versus placebo to reduce preopera-
tive transfusion that were conducted over a 15-year period
[1]. This meta-analysis identified that the estimate of ef-
fectiveness stabilized at the twelfth study and demon-
strated reduced bleeding with aproptinin. After this study,
nearly 3,000 further patients were randomized to control
groups in subsequent RCTs and were thus denied a treat-
ment that at that time was of proven effectiveness.
The timing of initiation of an RCT raises ethical as
well as scientific issues. Physician-researchers are widely
regarded as having a duty of care to patients in RCTs,
meaning that there must be good grounds to believe that
study interventions are consistent with standards of
medical care [2]. This ethical requirement, known as
“clinical equipoise”, demands that, at the start of an
RCT, there be a state of honest, professional disagree-
ment in the community of expert practitioners as to the
preferred treatment [3]. Yet, it is unclear which factors
contribute legitimately to the professional disagreement
central to clinical equipoise. Some argue that physicians
themselves must be uncertain as to the preferred treat-
ment, while others argue that the evidence supporting or
refuting a treatment must itself be incomplete or uncer-
tain [4]. Surprisingly little is actually known about how cli-
nicians determine whether an RCT is ethical, and the
factors to which they appeal in making this determination.
Our study context is the controversy surrounding the
role of selective decontamination of the digestive tract
(SDD) in preventing serious infections and mortality in
the critically ill [5]. Ventilator-associated pneumonia
(VAP) and other serious healthcare-associated infections
are important causes of morbidity and mortality in in-
tensive care units (ICUs). SDD involves the application
of topical antibiotics to the oropharynx and stomach
combined with a short course of intravenous antibiotics.
Evidence supporting the effectiveness of SDD includes
37 RCTs (involving more than 7000 patients) that have
been summarized in 12 meta-analyses and demonstrates
that SDD reduces VAP (odds ratio (OR) = 0.28; 95 %
confidence interval (CI) = 0.20–0.38) and mortality
(OR = 0.73; CI = 0.64–0.84) [6–8]. (A comprehensive
overview of the evidence supporting SDD may be found
in a recently publication by Price and colleagues [8].) Des-
pite such strong evidence, however, recommendations in
professional guidelines are inconsistent, and SDD is not
widely used in practice. A UK survey revealed that SDD
was used in only 10–15 of 240 ICUs [9]. Clinicians may be
reluctant to adopt SDD because of concerns about anti-
biotic resistant organisms, the applicability of RCTs con-
ducted in other countries, or skepticism about its
effectiveness [10].
The controversy over SDD thus provides a unique op-
portunity to explore how clinicians think about the eth-
ics of future RCTs. The disparity between the strength of
the evidence in favour of SDD, and the reluctance to use
it in clinical practice, is stark. It is unclear that further
trials would provide further clarity about clinical effect-
iveness. We asked the following research questions:
How do clinicians determine whether another RCT of
SDD is ethical? In making this determination, do they
appeal to the evidence base, clinical practice, opinion, or
other factors?
Methods
Cuthbertson and colleagues studied the perceived risks,
benefits, and barriers to the use of SDD in ICUs in
Australia, Canada, and the UK [11]. We undertook a
secondary analysis of SuDDICU (Selective Decontamin-
ation of the Digestive Tract in the ICU) clinician inter-
view data using a general description approach [12–14].
Ethics approval for this secondary analysis was obtained
through the University of Toronto Research Ethics
Board; written consent had been collected prior to each
interview in the primary study and was not required
again for this analysis. Clinicians, including 141 ICU
physicians, ICU pharmacists, ICU clinical leads, clinical
microbiologists, and infectious disease specialists, were
asked how they perceived the effectiveness of SDD and
whether further research, including additional RCTs,
was required [15]. The original data were collected in a
semi-structured interview utilizing the Theoretical Do-
mains Framework, facilitated by a topic guide developed
by the multi-disciplinary research team using methods
described elsewhere [11, 16]. Our study met the criteria
for re-usability of qualitative data set out by Hinds in ac-
cordance with the key dimensions of: 1) accessibility (we
conducted the original research); 2) quality (the original
research design was publishable, the data set was
complete, and a full summary was made of all analysis
meetings held over a 12-month period); 3) suitability
(the selected participants matched the emerging themes
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we identified and additional interviews were not re-
quired to achieve theoretical saturation) [17].
Using Braun and Clarke’s thematic approach, three re-
searchers (FW and CW and LT) independently reviewed
an initial series of nine purposively chosen transcripts
from Canadian clinicians and then met to establish a
coding framework [18]. LT then coded additional tran-
scripts using this framework. This is a secondary analysis
so, for the analysis reported here, recruitment was
already completed at the study sites. The team con-
cluded that saturation had been reached at 18 interviews
within the Canadian data set [19]. A decision was made
by the team to extend our analysis to include 18 tran-
scripts each from the UK and Australia (with six partici-
pants from each of three professional groups: critical
care physicians, pharmacists, and infectious disease spe-
cialists) where interviews were conducted over the same
time period using the same interview guide. Our ap-
proach to sampling was based on maximum variation
sampling, which involves selecting typical, atypical, and
“information-rich cases” [20]. Researchers involved in
data collection at the Canadian, Australian, and UK sites
were asked to identify transcripts that seemed represen-
tative as well as any outliner accounts or transcripts that
provided particularly information rich cases of inter-
professional collaboration and decision making in rela-
tion to scientific evidence. We extrapolated the number
of 18 required to reach saturation from the Canadian
data set to the other data sets. Given nurses’ consistent
statements that they were not involved in decisions
about trial participation, they were not represented in
this data set.
After data coding, we then focused our interpretation
to identify similarities and differences across the inter-
views. This step involved combining codes into themes
and searching for patterns. Researchers’ comments were
recorded as marginal notes during six meetings in the
coding/theme development phase to assist focus around
emerging concepts. The analysis was between interpreta-
tions (CW, FW, and LT) that were captured in notes
taken after every meeting. More than one investigator
performed each step during this analysis. We discussed
our biases during data analysis and recorded these con-
versations through the use of investigator memos to help
ensure that our analysis was reflexive [21].
Results
We analyzed 54 transcripts in this study, from interviews
with 18 critical care physicians, 18 pharmacists, and 18
infectious disease specialists from Australia, Canada, and
the UK. In our study, clinicians frequently described the
factors external to the evidence that contributed to their
decision making regarding the ethics of future RCTs.
We grouped their responses into four inter-related
themes: 1) cultural norms about evidence and practice
within healthcare practice, including a belief about the
infallibility of guidelines; 2) personal views about what
evidence is current or applicable; 3) interpersonal and
relational aspects of professional decision making locally;
and 4) an a priori commitment to future trials testing
SDD. Each of these factors was identified by participants
as influencing their uptake of evidence and decision
making regarding the ethics of future SDD trials. (See
Additional file 1: Table S1 for additional quotes.)
Theme 1: cultural norms within healthcare practice
Participants’ conceptualization and understanding of the
evidence, and how they utilized it in their own decision
making, revealed several strongly articulated cultural
norms within critical care about evidence and practice.
While clinicians adhere publicly to the concept of
evidence-based medicine (EBM), those in our study ex-
plained that evidence alone is insufficient to determine
practice. Views about the use of evidence did not vary
by geographic location or profession. For example:
“… physicians are a strange bunch, because they’ll all
tell you that they want to see evidence before adopting
a practice, and yet often they do things that… go
against evidence or… are based on sort of one-off expe-
riences they’ve had… I think physicians are a little bit
difficult in that way.” (Infectious Disease Physician,
Canada, 025)
The reasons given by participants for not following
evidence varied but were seldom based on methodo-
logical criticism of supporting evidence or appeal to
contradictory evidence. For some, resistance to evidence
was related to maintaining one’s professional reputation.
One critical care physician described how adopting new
evidence might call into question the validity of previous
practices, suggesting that:
“… people [might] now not be willing to change their
mind regardless of the evidence because to do so at
this point would almost undermine all the years that
they actually said it didn’t work.” (Critical Care
Physician, UK, 210)
Many interviewees also described regularly following
practices which were not evidence-based. One partici-
pant cited collegial agreement and potential lack of
harm, to justify engaging in practices for which there is
“quite poor evidence”:
“the head of bed elevation…even though [it has] quite
poor evidence … and especially even when compared
to SDD, people will say, ‘Well, what’s the big deal… in
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just elevating the head of the bed? It’s an easy thing to
do’… the science behind it’s bad, but people just
agree….” (Critical Care Physician, Canada, 043)
Another cultural norm that emerged from our inter-
views was deference to guidelines. Many participants
were unwilling to trust their own critical appraisal of the
evidence if this meant going against norms or guidelines.
As one participant argued:
“I think because the national and international bodies
haven’t come out… jumping up and down and saying
it’s a good thing to do that everyone’s a bit leery to
strike out on their own”. (Critical Care Physician,
Canada, 315)
In relation to the evidence for SDD specifically, some
physicians felt that there was strong evidence to adopt
SDD yet similarly strong resolve to not adopt it:
“it’s been very interesting that it’s not adopted, yet
evidence would suggest it should be and, and it’s
almost actively not adopted if you know what I mean.
It’s the … best example we have against evidence-
based medicine. Despite a level of evidence we’re happy
to apply to other things … it still isn’t incorporated into
practice…” (Critical Care Physician, Australia, 210)
Theme 2: personal views about what ideas are current or
applicable
For some participants, their personal view that the ef-
fectiveness of SDD is “old news” was a salient factor in
their decision making. Although evidence is meant to be
cumulative, in practice it turns out that the interpret-
ation of evidence might more often be cyclical. In the
current climate of rapidly produced new evidence, “old
news” evidence might not be implemented despite its
solid grounding in science. As one participant noted:
“I think [there have] been various iterations of SDD
over the years and it’s come and gone in terms of
fashion. I remember in 1993 … it was quite
fashionable to do it at that stage and then it went out
of vogue and more recently it’s come back into vogue
again and … has been a bit cyclical in its history.”
(Critical Care Physician, Australia, 044)
In addition, several participants considered that the re-
sults of trials that had been conducted in other countries
were not relevant or applicable in their own. This held true
even when patient populations and healthcare systems were
relatively similar across countries. For example, one Canad-
ian pharmacist indicated that he considered studies con-
ducted in Europe to have “different microbial flora, [and a]
different patient population (Pharmacist, Canada, 013),
while a critical care physician in Australia believed
that, before making a decision to implement as a
“standard of practice”, they would need to see:
“evidence replicated in a setting outside of Northern
Europe, preferably in Australia” (Critical Care
Physician, Australia, 301)
Theme 3: interpersonal and relational aspects of
professional decision making locally
Participants in Australia and Canada expressed their
perception that members of other professional groups
had differing beliefs or priorities with respect to SDD. For
example, some critical care physicians described their infec-
tious disease colleagues as being singular in their “concern
about the possibility of resistant organisms” and further in-
dicated that in their hospital, “antibiotic usage is con-
trolled by the microbiologists …” (Critical Care
Physician, Australia, 304).
On the other hand, some of the infectious disease physi-
cians explained their concerns about SDD and antibiotic
resistance, concerns which they felt were overlooked by
the intensivists::
“The intensivists might be embracing this with open
arms, but unfortunately the intensivists aren’t really
concerned with anything outside the doors of the
ICU… a disaster created in the ICU… becomes a
disaster on the ward and the rest of the hospital, so
the intensivists have to remember that what they do in
their little area could have grave implications system-
wide.” (Infectious Disease Physician, Canada, 044)
Within their professional groups many participants
insisted that decisions were made on a team basis:
“And I think also we try where we can to do most
things in a sort of … collegiate fashion with consensus
rather than having one person implementing things.”
(Critical Care Physician, UK, 304)
Nonetheless, many participants also specified that one
particular individual (often the head of a unit or depart-
ment) had decision-making authority within their unit.
“Because I’m external to the ICU the decisions on
protocols are basically made by the director of the ICU
… so if the director of our ICU felt very strongly in favour
of something and we didn’t like it, you would do it
anyway. (Infectious Disease Physician, Australia, 405)
Still other participants seemed steadfast in their con-
viction that they would never adopt SDD.
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“[In order to adopt SDD in my unit] someone would
have to assassinate me.”
(Infectious Disease Physician, Canada, P10)
Theme 4: an a priori commitment to future trials
Several participants expressed their belief that future tri-
als were unnecessary or infeasible:
“I don’t know how many times you have to beat people
over the head with a stick for them to get it. I guess if
there was to be more research, well, what would it
be?… at some point I think people either have to buy
into it or you have to move on to a different topic”.
(Critical Care Physician, Canada, 022)
Many participants clearly supported this opinion that
a future trial was unnecessary, suggesting that such a
trial would be:
“just wasting everybody’s time because I think the
people… have got their mind set up against it”
(Infectious Disease Physician, UK, 1704).
“We do a lot of research but I guess I can’t really see
how [testing implementation strategies] is research. It’s
more implementation of a treatment which probably
has evidence.” (Critical Care Physician, Australia, 304)
Paradoxically, many of these same participants expressed
a willingness to participate in future effectiveness trials:
“I am not convinced there is overwhelming evidence
that we should all be doing it because if there was
overwhelming evidence that we should all be doing it,
then we would all be doing it. Therefore I think there
is still a potential for more research.” (Pharmacist, UK,
3603)
“Oh absolutely I think there’s, I think there’s equipoise
on this issue and so [a trial] is absolutely justifiable.”
(Infectious Disease Physician, Australia, 401)
“I think it [a trial] is ethical because there is a huge, I
think there is equipoise within the medical profession.”
(Critical Care Physician, UK, 1701)
Discussion
Our study found that the descriptions which clinicians
provided of their ethical decision making and practice
were significantly influenced by the “extra-evidential” fac-
tors described above (that is, cultural norms about evi-
dence and practice within healthcare practice, including a
belief about the infallibility of guidelines and personal
biases about what evidence is current or applicable).
Interestingly, these norms transcended professional and
geographical boundaries. Physicians in our study did ap-
peal directly to the concept of clinical equipoise but based
their assessment of whether clinical equipoise obtains on
socio-organizational types of factors, including practice
norms, personal opinion, and clinical experience. Equi-
poise is a term frequently used in discussions of clinical
trials. Yet, despite the discursive centrality of this concept
in the ethical justification for clinical trials, there is a sur-
prising lack of empirical research exploring physicians’
views and practices. The current study addresses this gap
and provides evidence that such “extra-evidential” reasons
influence ethical decision making to a much greater extent
than previously recognized.
In our analysis we paid particular attention to incon-
sistencies within and between participants’ accounts of
their use of evidence in clinical and ethical decision
making. We found many statements that contradicted
the notion that clinicians undertook an objective ap-
praisal of scientific evidence when making decisions re-
garding the ethics of future RCTs on this topic. In
general, participants described a widespread tendency to
ignore scientific evidence and to accept published guide-
lines uncritically as a substitute for individual appraisal
of evidence. This is particularly interesting, and may
seem surprising in light of the longstanding problems re-
lated to variability in physician adherence to published
guidelines and the difficulty in increasing guideline ad-
herence [22].
The social context in which clinicians practice greatly
influences their perceptions. In an important qualitative
study by Donovan et al. [23], researchers found that
“Many doctors acknowledged that they had ’hunches‘ or
’gut instincts‘ that particular treatments were superior in
general or for specific patients or groups, and many ex-
perienced discomfort because of their clinical instincts
and the ’blurring‘ of equipoise around rigid RCT eligibil-
ity criteria”. As noted above, evidence may also be per-
ceived as cyclical rather than cumulative. Some
practitioners referred to evidence supporting SDD as
“old news” while others stated that implementing the
evidence about SDD would first require personal “buy-
in”. The role played by the clinical team in assessing evi-
dence is complex and, at times, contradictory. Clinicians’
membership in specific subspecialties seemed to influ-
ence their interpretation of the evidence in relation to
the relative importance of perceived benefits and harms.
Infectious disease specialists, not unsurprisingly, focused
on concerns about population antibiotic resistance rates,
while critical care physicians expressed more concern
for individual patient welfare. Moreover, physicians from
one specialty spoke about their colleagues from another
professional group in terms that seemed at times stereo-
typical, such as the notion that critical care physicians
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“aren't really concerned with anything outside the doors
of the ICU”. Professional polarization thus had a signifi-
cant impact on the way clinicians think about issues
such as whether they should focus on the individual pa-
tient under their current care (the ethical principle of
beneficence) or the well-being of future patients (the
principle of justice). These questions of values cannot be
resolved by appealing to scientific evidence alone.
A number of critics argue that the current thinking on
EBM ignores the relational aspects of knowledge and
dismisses the role of values in healthcare [22]. For such
critics, “the clinician can often be considered… an insti-
tutional subject who is presumed both to know the truth
of disease and to have the moral and intellectual author-
ity to prescribe treatment” [24]. However, proponents of
EBM have pointed out that values play a role in every
important patient care decision [25]. Our qualitative
study of clinicians’ reasoning about current SDD prac-
tice and future SDD trials highlights how decisions are
sometimes consistent with individual values, or group
values or societal values. The subjective and relational
aspect of knowledge is particularly significant in ac-
counts of how the ethics of future research are deter-
mined. Many individual clinicians demonstrate a type of
“group think”, expressing a strong adherence to deci-
sions made by the local team [26]. This supports our
contention that there are interpersonal and relational in-
fluences involved in clinical reasoning that transcend the
role played by individual reasoning. Contradictions were
also apparent between how clinicians thought decisions
ought to be made (by the team), and how they actually
were made in practice (by a key individual who held a
leadership position). We found these inconsistencies to
persist across various professional disciplines and across
the three international regions involved in our study. The
majority of participants expressed their faith in EBM while
acknowledging the prevalence of non-scientific factors in
clinical decision making. As noted elsewhere, EBM is as
much a discourse as an actual practice and, as our findings
suggest, its widespread adoption tends to obscure prac-
tices that are not necessarily exclusively scientifically
informed.
Limitations
One of the limitations of secondary analysis of qualita-
tive data is a lack of involvement in generating the ori-
ginal data set. Our original use of the Theoretical
Domains Framework in the primary study, however, re-
sulted in the generation of rich, in-depth data, which
mitigated this challenge. Given the large number of in-
terviews originally conducted, we were able to purpos-
ively select transcripts and believe that saturation was
reached. We identified “key stakeholder groups” to par-
ticipate in this study but did not include all possible
stakeholders in our analysis. In addition, our choice of
SDD as an example presents a case in which strong ran-
domized trial evidence has not been adopted in practice.
Therefore, it presents a special case, and our findings
may not be generalizable to other interventions. Further
limitations may include the study being performed in
English-speaking countries only and in countries where
SDD implementation is low.
Conclusion
We sought to ascertain how clinicians decide whether
future RCTs in a field are ethical. This study reveals that,
regarding SDD, ethical decision making did not rely
strongly on appeals to evidence, even when the quality
of the evidence is quite high. Clinicians from different
specialities and different geographical regions consist-
ently described having been influenced by extra-
evidential factors in their day-to-day practice and in
their willingness to participate in future trials. These
extra-evidential factors include social, professional, and
relational contexts. When clinicians appeal to factors
other than the evidence base, it can have a significant
impact on their willingness to design, conduct, and enrol
patients into future RCTs or may limit their willingness
to implement “apparently proven” therapies into their
practices. Further work is required to see if these con-
clusions are applicable to other clinical topics and
settings.
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